NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — Levi & Korsinsky is notifying investors that it has opened an investigation into Relmada Therapeutics, Inc. (“Relmada” or the “Company”) RLMD about potential violations of federal securities laws.

Ahead of market opening on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303) evaluating the drug REL-1017 as a monotherapy for major depressive disorder (MDD). Relmada revealed that the RELIANCE III study did not meet its primary endpoint of a statistically significant improvement in depression symptoms compared to placebo at Day 28 as measured by the Mongomery-Asberg Depression Rating Scale (MADRS). Specifically, REL-1017 treatment demonstrated a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher than expected placebo response. Relmada described that “[p]Aradoxic results were observed at certain study sites, where placebo significantly outperformed REL-1017.”

Following this news, Relmada’s share price fell nearly 80% to close at $6.48 per share on October 13, 2022. For more information, go to:

https://zlk.com/pslra-1/relmada-lawsuit-submission-form?wire=3

or contact Joseph E. Levi, Esq. either by email at jlevi@levikorsinsky.com or by calling (212) 363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, the Levi & Korsinsky team has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive experience representing investors in complex securities disputes and has a team of over 70 professionals dedicated to serving our clients. For seven consecutive years, Levi & Korsinsky has been ranked in the Top 50 Report by ISS Securities Class Action Services as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, Suite No. 427
New York, New York 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212)…